Calcineurin Inhibitors

Overview

Calcineurin inhibitors are a class of immunosuppressive therapies that suppress T-cell activation by inhibiting the phosphatase calcineurin, thereby reducing downstream signaling required for cytokine production and adaptive immune responses. In clinical practice, this drug class is most commonly represented by tacrolimus, and it is widely used in transplantation medicine and selected immune-mediated diseases.

Their principal medical significance lies in preventing graft rejection and controlling immune activation, but their use is balanced against important toxicities, especially nephrotoxicity and other adverse effects related to chronic immunosuppression. Recent research continues to examine how calcineurin inhibitors interact with immune regulation, tissue injury, microbiome composition, and combination immunosuppressive strategies involving agents such as sirolimus, mycophenolate mofetil, and tyrosine-kinase inhibitor-based regimens.

Focus of Latest Publications

Recent publications have continued to examine calcineurin inhibitors, particularly tacrolimus, across transplant and non-transplant settings. In a large national retrospective cohort of deceased-donor kidney transplant recipients, maintenance regimens containing a calcineurin inhibitor plus mycophenolate mofetil were associated with lower hazards of both death-censored graft failure and all-cause patient mortality, with or without steroids. In the same study, induction strategies varied in their associations with outcomes, and the authors concluded that calcineurin inhibitor-based maintenance remained favorably associated with long-term transplant outcomes. Another transplant-focused study evaluated topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty, aiming to describe graft rejection incidence and clinical features over four years.

Several recent reports also explored tacrolimus in disease-specific immunotherapy and local drug delivery. In adult-onset mild-to-moderate myasthenia gravis, tacrolimus monotherapy was assessed for remission, relapse, and safety. In a tracheal wound-healing model, tacrolimus was incorporated into a chitosan nanoparticle-polylactic acid nanofiber composite membrane, where it was released over 28 days and was reported to suppress hypertrophic scar fibroblast activity while supporting normal tracheal repair in vitro and in a mouse trauma model. In peripheral nerve repair research, locally applied FK506 was tested alongside PEG-fusion of viable sciatic nerve isografts; although PEG-fusion improved axonal morphology and behavioral recovery, FK506 only transiently improved regeneration and impaired long-term functional recovery.

Other studies focused on tacrolimus-associated biology and toxicity. In pediatric solid organ transplant recipients, tacrolimus levels were associated with the degree of gut microbiota dysbiosis and altered secretory IgA targeting, suggesting an immune-mediated link between immunosuppression, human gut flora composition, and persistent dysbiosis. In a rat model of reduced renal reserve, low-dose tacrolimus exacerbated renal dysfunction, albuminuria, and interstitial fibrosis, while concomitant everolimus was associated with partial attenuation of these changes. Together, these publications highlight ongoing interest in calcineurin inhibitors as both systemic and locally delivered therapies, as well as their long-term efficacy, safety, and tissue-specific effects.

A related mechanistic study compared tacrolimus with CD40 blockade in immune cells and noted that iscalimab had limited clinical benefit relative to standard tacrolimus treatment in transplantation. In vitro, the anti-CD40 antibody inhibited B-cell proliferation but showed limited to no efficacy against activated CD4 T-cell proliferation, including autoreactive and alloreactive responses, underscoring the continued relevance of calcineurin inhibitor-based immunosuppression in T-cell–mediated settings.

Key Publications

NEWJun Immunosuppressive regimens and long-term kidney transplant outcomes: A dual survival modeling framework. (PloS one, 2026, PMID 42361104): "Maintenance regimens incorporating calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) were associated with lower hazards for both graft failure."
NEWJun Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study. (International ophthalmology, 2026, PMID 42319541): "To describe the incidence and clinical profile of graft rejection in high-risk penetrating keratoplasty (PK) recipients treated with a compounded topical formulation of 0.02% tacrolimus combined with 1% prednisolone."
NEWJun Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. (PloS one, 2026, PMID 42284279): "Since iscalimab showed limited clinical benefit and did not improve kidney and liver transplantation outcomes compared to standard tacrolimus treatment, we studied whether a biosimilar of iscalimab affects T cell responses in vitro."
Jun Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety. (CNS neuroscience & therapeutics, 2026, PMID 42223343): "to evaluate the safety of tacrolimus monotherapy (TAMO) in adult-onset mild-to-moderate myasthenia gravis (MG)."
May Altered SIgA-targeting of gut microbiota is associated with long-term dysbiosis in pediatric solid organ transplant recipients. (Gut microbes, 2026, PMID 42178721): "We confirmed compositional and functional dysbiosis in SOT recipients, with the degree of dysbiosis being associated with tacrolimus (TAC) levels."
May PEG-fusion of viable sciatic nerve isografts restores axonal structure and behavioral recovery after segmental-loss sciatic nerve injuries in Lewis rats. (PloS one, 2026, PMID 42166429): "We also examined the effects of locally applied FK506 on 10-mm VPNI repairs both with and without PEG-fusion."
Jun Chitosan nanoparticles-incorporated polylactic acid/tacrolimus nanofiber composite membrane for tracheal scar inhibition and tracheal wound healing promotion. (International journal of biological macromolecules, 2026, PMID 42107578): "We hypothesized that a composite membrane integrating chitosan (CS), polylactic acid (PLA), and tacrolimus (TAC) via simultaneous electrospinning and electrospraying would inhibit tracheal scarring and promote tracheal wound healing by synergizing their respective advantages."
May Tacrolimus-accelerated renal interstitial injury in subtotal nephrectomized rats and its pharmacological modulation by everolimus. (Toxicology letters, 2026, PMID 42061595): "Tacrolimus, a calcineurin inhibitor widely used in clinical practice, is associated with chronic nephrotoxicity, particularly under conditions of reduced renal reserve."